WASHINGTON, D.C. -- Cornell University, with support from the Foundation for Prevention and Early Resolution of Conflict (PERC), plans to establish an institute at the School of Industrial and Labor Relations for the study of conflict resolution. The institute, to be located on the Cornell campus in Ithaca, N.Y., is expected to open in August 1996.
ITHACA, N.Y. -- "You could be a bricklayer," adults suggested kindly to the husky youth, Kevin Wallace, although they didn't think he even had the brains for that. And teachers were less charitable, in the days before dyslexia-type reading and learning disorders were understood, Wallace remembers: "I asked the nun how I could make the letters hold still on the page, and she said the devil was working in me." Repeatedly punished without knowing why, he carried feelings of shame and confusion until age 28. Then Wallace confessed to his 7-year-old daughter the reason he told such marvelous bedtime stories but never read them: He couldn't read, a secret he withheld from employers, friends and even from Thea, his wife. Today, the other 76 graduates of Cornell University's College of Veterinary Medicine D.V.M. Class of '97 are in awe of a phenomenal power Wallace developed, while managing his learning disability. It is said he somehow absorbed so much information about veterinary medicine that he can read an ailing animal like a . Better, actually, than a book, of which he figures he has read two.
In September at the United Nations, President Clinton and leaders of four other superpowers signed the Comprehensive Test Ban Treaty, prohibiting the testing of nuclear devices around the globe. As of January, 140 nations had signed on.
Walter LaFeber is a historian who relishes being one of the "old school" types with a sense of humor, a warmth and wisdom grounded in the fundamentals that come from cultivating a long view, whether it be in foreign relations history or baseball. And oh my, are we going to miss him.
The Cornell University Institute for Animal Welfare has been established to foster discussion and research on issues concerning animals in agriculture, laboratories and the wild.
Andrew D. White, first president of Cornell University, was a bookish man -- a scholar who knew, loved and collected books. Though the university's founder, Ezra Cornell, was not bookish, he appreciated the value and necessity of assembling a proper library for the students and faculty of the university that was to bear his name.
Scientists hoping to produce super-tough, bio-inspired fibers are a step closer with a new model for the molecular arrangement of spider silk, proposed by Cornell researchers in the Jan. 5 issue of the journal Science. Alexandra H. Simmons, Carl A. Michal and Lynn W. Jelinski reported their findings in the article, "Molecular Orientation and Two-component Nature of the Crystalline Fraction of Spider Dragline Silk."
Scientists hoping to produce super-tough, bio-inspired fibers are a step closer with a new model for the molecular arrangement of spider silk, proposed by Cornell University researchers in the Jan. 5 issue of the journal Science.
The seventh Cornell Council for the Arts Individual Grants exhibition opens Jan. 11 at the Herbert F. Johnson Museum of Art on the Cornell University campus. The exhibition features the work of nine artists who were awarded the grants in either 1992, 1993 or 1994.
New York, NY (August 20, 2003) -- Surgeons at New York Weill Cornell medical center performed the world's first gene therapy for Parkinson's disease on a 55-year-old New York man on Monday, August 18. The historic surgery, which also marked the first-ever in vivo gene therapy in the brain for an adult neurological disease, was part of a phase I clinical trial approved by the Food and Drug Administration in October 2002. The five-hour procedure was performed by Dr. Michael G. Kaplitt, Director of Stereotactic and Functional Neurosurgery at NewYork-Presbyterian Hospital and Assistant Professor of Neurological Surgery at Weill Cornell Medical College. The patient is recovering normally and is expected to return home today, just two days after the surgery was performed."Monday's surgery represents the realization of nearly 15 years of research in this area," said Dr. Kaplitt. "The goal of our gene therapy approach is to 're-set' a specific group of cells that have become overactive in an affected part of the brain, causing the impaired movements associated with Parkinson's disease. We hope that this trial, which is the first of its kind, will prove to be a safe treatment to allow gene therapy to move forward for Parkinson's disease and other brain disorders."